ago2 Search Results


94
Sino Biological ago2 expression
Creation and genomic characterisation of <t>AGO2-HaloTag</t> cell Lines(A) schematic of WT AGO2 and the C terminal AGO2-HaloTag fusion (including T2A site, puromycin resistant (PuroR) and Poly(A) sections) genotype to be generated by CRISPaint editing of A549 cells. Arrows indicate locations of forward and reverse primers designed to confirm editing. Blue = AGO2 WT last intron forward and reverse; Light Teal = HaloTag1 forward and reverse; Dark Teal = HaloTag2 forward and reverse.(B) agarose gel loaded with PCR products of A549 WT and two AGO2-HaloTag (AGO2-HaloTag C5 and AGO2-HaloTag C10) lines amplified with indicated combinations of AGO2 WT and HaloTag primers, as indicated in (A). Red arrows indicate gDNA containing HaloTag sequence which was purified and submitted for sequencing. Circled numbers 1–3 indicate gDNA containing C terminal non-HaloTagged AGO2 product which was purified and submitted for sequencing. (C) sequence (generated from TOPO-seq) alignments of WT and two AGO2-HaloTag clones at the AGO2-HaloTag junction. From several submitted TOPO clones, two variants of AGO2-HaloTag (one long and one short) were identified in AGO2-HaloTag cells. Asterisk (*) indicates STOP codon. (D) schematic to show known functionally important domains of AGO2, with a focus on C-terminal PIWI domain. CRISPaint mediated AGO2-HaloTag fusion generated a long and a short variant. (E) chromatograph of C terminal AGO2 sequence identified in WT, AGO2-HaloTag C5 and AGO2-HaloTag C10 cells (circled numbers 1–3 in (B)) showing the additional and premature STOP codon in both AGO2-HaloTag lines. (F) abundance of untagged AGO2 mRNA transcript in A549 WT, two UnTagged (UT C1 and UT C2) and two AGO2-HaloTag (AGO2-HaloTag C5 and AGO2-HaloTag C10) cells. AGO2 (non-HaloTagged) mRNA abundance normalized to B Actin mRNA abundance and made relative to levels in WT cells. Data represent mean ± SEM of experiments; n = 3 (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001). (G & H) Western blot of whole-cell lysates from A549 WT, two UnTagged (UT C1 and UT C2) and two AGO2-HaloTag (AGO2-HaloTag C5 and AGO2-HaloTag C10) cell lines probed with antibodies against AGO2, HaloTag, and beta Actin.
Ago2 Expression, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ago2 expression/product/Sino Biological
Average 94 stars, based on 1 article reviews
ago2 expression - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

96
TaKaRa anti human ago2 monoclonal antibody
Creation and genomic characterisation of <t>AGO2-HaloTag</t> cell Lines(A) schematic of WT AGO2 and the C terminal AGO2-HaloTag fusion (including T2A site, puromycin resistant (PuroR) and Poly(A) sections) genotype to be generated by CRISPaint editing of A549 cells. Arrows indicate locations of forward and reverse primers designed to confirm editing. Blue = AGO2 WT last intron forward and reverse; Light Teal = HaloTag1 forward and reverse; Dark Teal = HaloTag2 forward and reverse.(B) agarose gel loaded with PCR products of A549 WT and two AGO2-HaloTag (AGO2-HaloTag C5 and AGO2-HaloTag C10) lines amplified with indicated combinations of AGO2 WT and HaloTag primers, as indicated in (A). Red arrows indicate gDNA containing HaloTag sequence which was purified and submitted for sequencing. Circled numbers 1–3 indicate gDNA containing C terminal non-HaloTagged AGO2 product which was purified and submitted for sequencing. (C) sequence (generated from TOPO-seq) alignments of WT and two AGO2-HaloTag clones at the AGO2-HaloTag junction. From several submitted TOPO clones, two variants of AGO2-HaloTag (one long and one short) were identified in AGO2-HaloTag cells. Asterisk (*) indicates STOP codon. (D) schematic to show known functionally important domains of AGO2, with a focus on C-terminal PIWI domain. CRISPaint mediated AGO2-HaloTag fusion generated a long and a short variant. (E) chromatograph of C terminal AGO2 sequence identified in WT, AGO2-HaloTag C5 and AGO2-HaloTag C10 cells (circled numbers 1–3 in (B)) showing the additional and premature STOP codon in both AGO2-HaloTag lines. (F) abundance of untagged AGO2 mRNA transcript in A549 WT, two UnTagged (UT C1 and UT C2) and two AGO2-HaloTag (AGO2-HaloTag C5 and AGO2-HaloTag C10) cells. AGO2 (non-HaloTagged) mRNA abundance normalized to B Actin mRNA abundance and made relative to levels in WT cells. Data represent mean ± SEM of experiments; n = 3 (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001). (G & H) Western blot of whole-cell lysates from A549 WT, two UnTagged (UT C1 and UT C2) and two AGO2-HaloTag (AGO2-HaloTag C5 and AGO2-HaloTag C10) cell lines probed with antibodies against AGO2, HaloTag, and beta Actin.
Anti Human Ago2 Monoclonal Antibody, supplied by TaKaRa, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human ago2 monoclonal antibody/product/TaKaRa
Average 96 stars, based on 1 article reviews
anti human ago2 monoclonal antibody - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

94
Sino Biological anti ago2 primary antibody
<t>AGO2</t> and other protein factors involved in miRNA-mediated regulation can associate with chromatin. Western blots showing ( A ) AGO2 localization and purity of cytoplasm (CY), nucleoplasm (NP), and chromatin (CH) in wild-type samples ( N = 3), ( B ) purity [calnexin for endoplasmic reticulum (ER)] and localization of DROSHA, Dicer, TNRC6A, and AGO1–4 ( N = 3), and ( C ) AGO2 localization in the nuclear localization sequence (NLS)-AGO2 knock-in cell line ( N = 3).
Anti Ago2 Primary Antibody, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti ago2 primary antibody/product/Sino Biological
Average 94 stars, based on 1 article reviews
anti ago2 primary antibody - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

91
OriGene ago2
<t>AGO2</t> and other protein factors involved in miRNA-mediated regulation can associate with chromatin. Western blots showing ( A ) AGO2 localization and purity of cytoplasm (CY), nucleoplasm (NP), and chromatin (CH) in wild-type samples ( N = 3), ( B ) purity [calnexin for endoplasmic reticulum (ER)] and localization of DROSHA, Dicer, TNRC6A, and AGO1–4 ( N = 3), and ( C ) AGO2 localization in the nuclear localization sequence (NLS)-AGO2 knock-in cell line ( N = 3).
Ago2, supplied by OriGene, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ago2/product/OriGene
Average 91 stars, based on 1 article reviews
ago2 - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier

96
Proteintech antibodies for ago2
<t>AGO2</t> and other protein factors involved in miRNA-mediated regulation can associate with chromatin. Western blots showing ( A ) AGO2 localization and purity of cytoplasm (CY), nucleoplasm (NP), and chromatin (CH) in wild-type samples ( N = 3), ( B ) purity [calnexin for endoplasmic reticulum (ER)] and localization of DROSHA, Dicer, TNRC6A, and AGO1–4 ( N = 3), and ( C ) AGO2 localization in the nuclear localization sequence (NLS)-AGO2 knock-in cell line ( N = 3).
Antibodies For Ago2, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies for ago2/product/Proteintech
Average 96 stars, based on 1 article reviews
antibodies for ago2 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

91
Addgene inc human ago2
<t>AGO2</t> and other protein factors involved in miRNA-mediated regulation can associate with chromatin. Western blots showing ( A ) AGO2 localization and purity of cytoplasm (CY), nucleoplasm (NP), and chromatin (CH) in wild-type samples ( N = 3), ( B ) purity [calnexin for endoplasmic reticulum (ER)] and localization of DROSHA, Dicer, TNRC6A, and AGO1–4 ( N = 3), and ( C ) AGO2 localization in the nuclear localization sequence (NLS)-AGO2 knock-in cell line ( N = 3).
Human Ago2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human ago2/product/Addgene inc
Average 91 stars, based on 1 article reviews
human ago2 - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier

94
Sino Biological human ago2 recombinant protein
<t>AGO2</t> and other protein factors involved in miRNA-mediated regulation can associate with chromatin. Western blots showing ( A ) AGO2 localization and purity of cytoplasm (CY), nucleoplasm (NP), and chromatin (CH) in wild-type samples ( N = 3), ( B ) purity [calnexin for endoplasmic reticulum (ER)] and localization of DROSHA, Dicer, TNRC6A, and AGO1–4 ( N = 3), and ( C ) AGO2 localization in the nuclear localization sequence (NLS)-AGO2 knock-in cell line ( N = 3).
Human Ago2 Recombinant Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human ago2 recombinant protein/product/Sino Biological
Average 94 stars, based on 1 article reviews
human ago2 recombinant protein - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

94
Boster Bio ago2
SESN3 serve as a miR-23b sponge. ( A , B ) Expression changes of SESN3 following transfection with miR-23b mimics or inhibitor; ( C ) the predicted results of binding sites of SESN3 and miR-23b; ( D ) the sequence of psiCHECK2-circIGF1R-Wt and psiCHECK2-circIGF1R-Mut; ( E ) the results of dual-luciferase reporter assay; ( F ) the results of <t>AGO2-RIP</t> assay; ( G , H ) the results of miR-23b pulldown. Note: * indicted significant difference at 0.05 level, and ** indicted significant difference at 0.01 level.
Ago2, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ago2/product/Boster Bio
Average 94 stars, based on 1 article reviews
ago2 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

92
Addgene inc pcdna3 1
SESN3 serve as a miR-23b sponge. ( A , B ) Expression changes of SESN3 following transfection with miR-23b mimics or inhibitor; ( C ) the predicted results of binding sites of SESN3 and miR-23b; ( D ) the sequence of psiCHECK2-circIGF1R-Wt and psiCHECK2-circIGF1R-Mut; ( E ) the results of dual-luciferase reporter assay; ( F ) the results of <t>AGO2-RIP</t> assay; ( G , H ) the results of miR-23b pulldown. Note: * indicted significant difference at 0.05 level, and ** indicted significant difference at 0.01 level.
Pcdna3 1, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcdna3 1/product/Addgene inc
Average 92 stars, based on 1 article reviews
pcdna3 1 - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

93
Addgene inc ago2 expression vector
SESN3 serve as a miR-23b sponge. ( A , B ) Expression changes of SESN3 following transfection with miR-23b mimics or inhibitor; ( C ) the predicted results of binding sites of SESN3 and miR-23b; ( D ) the sequence of psiCHECK2-circIGF1R-Wt and psiCHECK2-circIGF1R-Mut; ( E ) the results of dual-luciferase reporter assay; ( F ) the results of <t>AGO2-RIP</t> assay; ( G , H ) the results of miR-23b pulldown. Note: * indicted significant difference at 0.05 level, and ** indicted significant difference at 0.01 level.
Ago2 Expression Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ago2 expression vector/product/Addgene inc
Average 93 stars, based on 1 article reviews
ago2 expression vector - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Addgene inc pcdna3 3 3xflag sumo eu1
KEY RESOURCES TABLE
Pcdna3 3 3xflag Sumo Eu1, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcdna3 3 3xflag sumo eu1/product/Addgene inc
Average 93 stars, based on 1 article reviews
pcdna3 3 3xflag sumo eu1 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

91
Addgene inc flag ha ago constructs
KEY RESOURCES TABLE
Flag Ha Ago Constructs, supplied by Addgene inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/flag ha ago constructs/product/Addgene inc
Average 91 stars, based on 1 article reviews
flag ha ago constructs - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier

Image Search Results


Creation and genomic characterisation of AGO2-HaloTag cell Lines(A) schematic of WT AGO2 and the C terminal AGO2-HaloTag fusion (including T2A site, puromycin resistant (PuroR) and Poly(A) sections) genotype to be generated by CRISPaint editing of A549 cells. Arrows indicate locations of forward and reverse primers designed to confirm editing. Blue = AGO2 WT last intron forward and reverse; Light Teal = HaloTag1 forward and reverse; Dark Teal = HaloTag2 forward and reverse.(B) agarose gel loaded with PCR products of A549 WT and two AGO2-HaloTag (AGO2-HaloTag C5 and AGO2-HaloTag C10) lines amplified with indicated combinations of AGO2 WT and HaloTag primers, as indicated in (A). Red arrows indicate gDNA containing HaloTag sequence which was purified and submitted for sequencing. Circled numbers 1–3 indicate gDNA containing C terminal non-HaloTagged AGO2 product which was purified and submitted for sequencing. (C) sequence (generated from TOPO-seq) alignments of WT and two AGO2-HaloTag clones at the AGO2-HaloTag junction. From several submitted TOPO clones, two variants of AGO2-HaloTag (one long and one short) were identified in AGO2-HaloTag cells. Asterisk (*) indicates STOP codon. (D) schematic to show known functionally important domains of AGO2, with a focus on C-terminal PIWI domain. CRISPaint mediated AGO2-HaloTag fusion generated a long and a short variant. (E) chromatograph of C terminal AGO2 sequence identified in WT, AGO2-HaloTag C5 and AGO2-HaloTag C10 cells (circled numbers 1–3 in (B)) showing the additional and premature STOP codon in both AGO2-HaloTag lines. (F) abundance of untagged AGO2 mRNA transcript in A549 WT, two UnTagged (UT C1 and UT C2) and two AGO2-HaloTag (AGO2-HaloTag C5 and AGO2-HaloTag C10) cells. AGO2 (non-HaloTagged) mRNA abundance normalized to B Actin mRNA abundance and made relative to levels in WT cells. Data represent mean ± SEM of experiments; n = 3 (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001). (G & H) Western blot of whole-cell lysates from A549 WT, two UnTagged (UT C1 and UT C2) and two AGO2-HaloTag (AGO2-HaloTag C5 and AGO2-HaloTag C10) cell lines probed with antibodies against AGO2, HaloTag, and beta Actin.

Journal: RNA Biology

Article Title: C-terminal tagging impairs AGO2 function

doi: 10.1080/15476286.2025.2534028

Figure Lengend Snippet: Creation and genomic characterisation of AGO2-HaloTag cell Lines(A) schematic of WT AGO2 and the C terminal AGO2-HaloTag fusion (including T2A site, puromycin resistant (PuroR) and Poly(A) sections) genotype to be generated by CRISPaint editing of A549 cells. Arrows indicate locations of forward and reverse primers designed to confirm editing. Blue = AGO2 WT last intron forward and reverse; Light Teal = HaloTag1 forward and reverse; Dark Teal = HaloTag2 forward and reverse.(B) agarose gel loaded with PCR products of A549 WT and two AGO2-HaloTag (AGO2-HaloTag C5 and AGO2-HaloTag C10) lines amplified with indicated combinations of AGO2 WT and HaloTag primers, as indicated in (A). Red arrows indicate gDNA containing HaloTag sequence which was purified and submitted for sequencing. Circled numbers 1–3 indicate gDNA containing C terminal non-HaloTagged AGO2 product which was purified and submitted for sequencing. (C) sequence (generated from TOPO-seq) alignments of WT and two AGO2-HaloTag clones at the AGO2-HaloTag junction. From several submitted TOPO clones, two variants of AGO2-HaloTag (one long and one short) were identified in AGO2-HaloTag cells. Asterisk (*) indicates STOP codon. (D) schematic to show known functionally important domains of AGO2, with a focus on C-terminal PIWI domain. CRISPaint mediated AGO2-HaloTag fusion generated a long and a short variant. (E) chromatograph of C terminal AGO2 sequence identified in WT, AGO2-HaloTag C5 and AGO2-HaloTag C10 cells (circled numbers 1–3 in (B)) showing the additional and premature STOP codon in both AGO2-HaloTag lines. (F) abundance of untagged AGO2 mRNA transcript in A549 WT, two UnTagged (UT C1 and UT C2) and two AGO2-HaloTag (AGO2-HaloTag C5 and AGO2-HaloTag C10) cells. AGO2 (non-HaloTagged) mRNA abundance normalized to B Actin mRNA abundance and made relative to levels in WT cells. Data represent mean ± SEM of experiments; n = 3 (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001). (G & H) Western blot of whole-cell lysates from A549 WT, two UnTagged (UT C1 and UT C2) and two AGO2-HaloTag (AGO2-HaloTag C5 and AGO2-HaloTag C10) cell lines probed with antibodies against AGO2, HaloTag, and beta Actin.

Article Snippet: Single-cell clones were screened for loss of AGO2 expression by immunoblotting using rabbit anti-AGO2 (Sino Biological 101,620-T36).

Techniques: Generated, Agarose Gel Electrophoresis, Amplification, Sequencing, Purification, Clone Assay, Variant Assay, Western Blot

Initial characterisation of AGO2-HaloTag cells Lines(A) doubling time of A549 WT, two UnTagged (UT C1 and UT C2) and two AGO2-HaloTag (AGO2-HaloTag C5 and AGO2-HaloTag C10) measured using IncucyteZoom over 108 hours. Data represent mean ± SEM; n = 3 (ns p > 0.05). (B) Representative Western blot of whole-cell lysates from indicated cell lines (harvested during log-phase) probed with antibodies against AGO1, AGO2, AGO3, AGO4, Vinculin. (C) Representative Western blot of whole-cell lysates from indicated cell lines (harvested during log-phase) probed with antibodies against DDX6, TNRC6A, LIMD1, and beta Actin. (D) densitometry of AGO1/2/3/4 (normalized to loading control (Vinculin)) in indicated cell lines. Data represents mean ± SEM; n = 3 (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001 according to one-way ANOVA test with Dunnett’s multiple comparisons). (E) densitometry analysis of drosha, exportin 5, Dicer, DGCR8, DDX6 andTNRC6A, (normalized to loading control (beta Actin or vinculin)) in indicated cell lines. Data represent mean ± SEM; n = 3 (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001).

Journal: RNA Biology

Article Title: C-terminal tagging impairs AGO2 function

doi: 10.1080/15476286.2025.2534028

Figure Lengend Snippet: Initial characterisation of AGO2-HaloTag cells Lines(A) doubling time of A549 WT, two UnTagged (UT C1 and UT C2) and two AGO2-HaloTag (AGO2-HaloTag C5 and AGO2-HaloTag C10) measured using IncucyteZoom over 108 hours. Data represent mean ± SEM; n = 3 (ns p > 0.05). (B) Representative Western blot of whole-cell lysates from indicated cell lines (harvested during log-phase) probed with antibodies against AGO1, AGO2, AGO3, AGO4, Vinculin. (C) Representative Western blot of whole-cell lysates from indicated cell lines (harvested during log-phase) probed with antibodies against DDX6, TNRC6A, LIMD1, and beta Actin. (D) densitometry of AGO1/2/3/4 (normalized to loading control (Vinculin)) in indicated cell lines. Data represents mean ± SEM; n = 3 (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001 according to one-way ANOVA test with Dunnett’s multiple comparisons). (E) densitometry analysis of drosha, exportin 5, Dicer, DGCR8, DDX6 andTNRC6A, (normalized to loading control (beta Actin or vinculin)) in indicated cell lines. Data represent mean ± SEM; n = 3 (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001).

Article Snippet: Single-cell clones were screened for loss of AGO2 expression by immunoblotting using rabbit anti-AGO2 (Sino Biological 101,620-T36).

Techniques: Western Blot, Control

Characterising AGO2 interactions, AGO2 localization and miR-451a levels in AGO2-HaloTag clones. (A) endogenous co-immunoprecipitation of AGO2 with Dicer and TNRC6A in WT, UnTagged C1 , UnTagged C2, AGO2-HaloTag C5 and AGO2-HaloTag C10 cells. Note the increased AGO2-Dicer and decreased AGO2-TNRC6A co-immunoprecipitation in AGO2 HALO cells compared to in WT and UnTagged cells. Histogram shows mean densitometry for TNRC6A IP normalized to AGO2 IP densitometry relative to WT A549 cells. Data represents mean of four independent repeats with * indicating p ≤ 0.05 according to one-way ANOVA test with Dunnett’s multiple comparisons. (B) immunoblots of nuclear and cytoplasmic fractions from WT. UnTagged C1 , UnTagged C2, AGO2-HaloTag C5 and AGO2-HaloTag C10 cells. Whole cell lysate (WCL) from WT A549 was also blotted alongside. Beta tubulin and histone H3 were probed as loading controls for cytoplasmic and nuclear fractions, respectively. (C) MiR-451a abundance (normalized to U6 RNA and made relative to relevant WT) in indicated cell lines measured by RT-qPCR using the 2 –∆∆Ct method. Data represent mean ± SEM; n = 2 (* p ≤ 0.05 according to one-way ANOVA test with Dunnett’s multiple comparisons). (D) pri-miR-451 abundance (normalised to beta actin mRNA levels) in indicated cell lines measured by RT-qPCR using the standard curve method. Data represent mean ± SEM; n = 2 (ns = not significant according to one-way ANOVA test with Dunnett’s multiple comparisons).

Journal: RNA Biology

Article Title: C-terminal tagging impairs AGO2 function

doi: 10.1080/15476286.2025.2534028

Figure Lengend Snippet: Characterising AGO2 interactions, AGO2 localization and miR-451a levels in AGO2-HaloTag clones. (A) endogenous co-immunoprecipitation of AGO2 with Dicer and TNRC6A in WT, UnTagged C1 , UnTagged C2, AGO2-HaloTag C5 and AGO2-HaloTag C10 cells. Note the increased AGO2-Dicer and decreased AGO2-TNRC6A co-immunoprecipitation in AGO2 HALO cells compared to in WT and UnTagged cells. Histogram shows mean densitometry for TNRC6A IP normalized to AGO2 IP densitometry relative to WT A549 cells. Data represents mean of four independent repeats with * indicating p ≤ 0.05 according to one-way ANOVA test with Dunnett’s multiple comparisons. (B) immunoblots of nuclear and cytoplasmic fractions from WT. UnTagged C1 , UnTagged C2, AGO2-HaloTag C5 and AGO2-HaloTag C10 cells. Whole cell lysate (WCL) from WT A549 was also blotted alongside. Beta tubulin and histone H3 were probed as loading controls for cytoplasmic and nuclear fractions, respectively. (C) MiR-451a abundance (normalized to U6 RNA and made relative to relevant WT) in indicated cell lines measured by RT-qPCR using the 2 –∆∆Ct method. Data represent mean ± SEM; n = 2 (* p ≤ 0.05 according to one-way ANOVA test with Dunnett’s multiple comparisons). (D) pri-miR-451 abundance (normalised to beta actin mRNA levels) in indicated cell lines measured by RT-qPCR using the standard curve method. Data represent mean ± SEM; n = 2 (ns = not significant according to one-way ANOVA test with Dunnett’s multiple comparisons).

Article Snippet: Single-cell clones were screened for loss of AGO2 expression by immunoblotting using rabbit anti-AGO2 (Sino Biological 101,620-T36).

Techniques: Clone Assay, Immunoprecipitation, Western Blot, Quantitative RT-PCR

Creation of AGO2 knockout A549, firefly luciferase assays and comparison of N - and C-terminally tagged AGO2. (A) Generation of AGO2 knockout A549 cells. Immunoblot of two AGO2 −/− clones alongside two control clones for AGO2 and beta actin as a loading control. (B) Relative firefly/Renilla luciferase activity in indicated cell lines transfected with reporter plasmids expressing firefly and Renilla luciferase and a siRNA against firefly luciferase (esi FFLuc ) or ‘non-targeting’ control (esi GFP ). The ratio between firefly and Renilla luciferase activity was measured 24 h after transfection. Data represent mean ± SEM; n = 3 (ns p > 0.05, **** p ≤ 0.0001 according to two-way ANOVA test with Sidak’s multiple comparisons). (C) Plasmid constructs for expression of untagged AGO2, EGFP-AGO2 and AGO2-EGFP. EGFP-VO is a control. (D) Relative firefly/Renilla luciferase activity in AGO2 −/− A549 transfected with reporter plasmids, AGO2 plasmids and an siRNA against firefly luciferase (esi FFLuc ) or ‘non-targeting’ control (scr). The ratio between firefly and Renilla luciferase activity was measured 24 h after transfection. Data represent mean ± SEM; n = 3 (ns p > 0.05; *** p ≤ 0.001, **** p ≤ 0.0001 according to one-way ANOVA test with Dunnett’s multiple comparisons). (E) Relative Renilla/firefly luciferase activity of a miR-100 targeted (T) reporter relative to a non-targeted (NT) reporter in AGO2 −/− A549 transfected with reporter plasmid, 15 nM miR-100 mimic and the indicated AGO2 constructs or EGFP-VO. Data represent mean ± SEM; n = 3 (ns p > 0.05; ** p ≤ 0.01 according to one-way ANOVA test with Dunnett’s multiple comparisons). (F) Immunoblots of nuclear and cytoplasmic fractions from AGO2 −/− A549 transfected with EGFP-VO, AGO2 UT, EGFP-AGO2 or AGO2-EGFP. Beta tubulin and histone H3 were probed as loading controls for cytoplasmic and nuclear fractions, respectively. (G) Fluorescence microscopy images for AGO2 −/− A549 transfected with EGFP-VO, EGFP-AGO2 or AGO2-EGFP. Cell nuclei are stained with DAPI and merged images show DAPI and EGFP signal combined. Scale bars indicate 10 µm. (H) UnTagged C1 and AGO2-HaloTag C10 cells treated with 100 nM HaloTag-TMR ligand visualized using confocal microscopy.

Journal: RNA Biology

Article Title: C-terminal tagging impairs AGO2 function

doi: 10.1080/15476286.2025.2534028

Figure Lengend Snippet: Creation of AGO2 knockout A549, firefly luciferase assays and comparison of N - and C-terminally tagged AGO2. (A) Generation of AGO2 knockout A549 cells. Immunoblot of two AGO2 −/− clones alongside two control clones for AGO2 and beta actin as a loading control. (B) Relative firefly/Renilla luciferase activity in indicated cell lines transfected with reporter plasmids expressing firefly and Renilla luciferase and a siRNA against firefly luciferase (esi FFLuc ) or ‘non-targeting’ control (esi GFP ). The ratio between firefly and Renilla luciferase activity was measured 24 h after transfection. Data represent mean ± SEM; n = 3 (ns p > 0.05, **** p ≤ 0.0001 according to two-way ANOVA test with Sidak’s multiple comparisons). (C) Plasmid constructs for expression of untagged AGO2, EGFP-AGO2 and AGO2-EGFP. EGFP-VO is a control. (D) Relative firefly/Renilla luciferase activity in AGO2 −/− A549 transfected with reporter plasmids, AGO2 plasmids and an siRNA against firefly luciferase (esi FFLuc ) or ‘non-targeting’ control (scr). The ratio between firefly and Renilla luciferase activity was measured 24 h after transfection. Data represent mean ± SEM; n = 3 (ns p > 0.05; *** p ≤ 0.001, **** p ≤ 0.0001 according to one-way ANOVA test with Dunnett’s multiple comparisons). (E) Relative Renilla/firefly luciferase activity of a miR-100 targeted (T) reporter relative to a non-targeted (NT) reporter in AGO2 −/− A549 transfected with reporter plasmid, 15 nM miR-100 mimic and the indicated AGO2 constructs or EGFP-VO. Data represent mean ± SEM; n = 3 (ns p > 0.05; ** p ≤ 0.01 according to one-way ANOVA test with Dunnett’s multiple comparisons). (F) Immunoblots of nuclear and cytoplasmic fractions from AGO2 −/− A549 transfected with EGFP-VO, AGO2 UT, EGFP-AGO2 or AGO2-EGFP. Beta tubulin and histone H3 were probed as loading controls for cytoplasmic and nuclear fractions, respectively. (G) Fluorescence microscopy images for AGO2 −/− A549 transfected with EGFP-VO, EGFP-AGO2 or AGO2-EGFP. Cell nuclei are stained with DAPI and merged images show DAPI and EGFP signal combined. Scale bars indicate 10 µm. (H) UnTagged C1 and AGO2-HaloTag C10 cells treated with 100 nM HaloTag-TMR ligand visualized using confocal microscopy.

Article Snippet: Single-cell clones were screened for loss of AGO2 expression by immunoblotting using rabbit anti-AGO2 (Sino Biological 101,620-T36).

Techniques: Knock-Out, Luciferase, Comparison, Western Blot, Clone Assay, Control, Activity Assay, Transfection, Expressing, Plasmid Preparation, Construct, Fluorescence, Microscopy, Staining, Confocal Microscopy

Structural insights of the C-terminal of AGO2 for an explanation of impaired function upon HaloTag insertion. (A) Schematic composition of AGO2 showing 7 main domains and motifs. (B) C-terminal residue A859 contributes to miRNA binding (PDB code: 4OLB). Residues shown in stick format and residue type and sequence number annotated. Dashed lines show inter-atom distances 5.0 Å. (C) Surface representation of AGO2 (4OLB) with domains coloured as in (A). Bound miRNA shown in spheres with 5ʹ-3ʹ direction indicated. The approximate location of the buried C-terminal residue A859 is indicated. (D) Surface representation of AGO2 (4OLB) showing sites of tryptophan binding and the N-terminal most residue (A22) seen in the electron density. Residues 1–21 were not observed in the data. (E) pLDDT values for predictions of native AGO2 (solid black line) and C-terminal halo-tagged AGO2 and relative solvent accessible surface area (QASA, Å 2 ; red line) calculated using PDB entry 4OLB .

Journal: RNA Biology

Article Title: C-terminal tagging impairs AGO2 function

doi: 10.1080/15476286.2025.2534028

Figure Lengend Snippet: Structural insights of the C-terminal of AGO2 for an explanation of impaired function upon HaloTag insertion. (A) Schematic composition of AGO2 showing 7 main domains and motifs. (B) C-terminal residue A859 contributes to miRNA binding (PDB code: 4OLB). Residues shown in stick format and residue type and sequence number annotated. Dashed lines show inter-atom distances 5.0 Å. (C) Surface representation of AGO2 (4OLB) with domains coloured as in (A). Bound miRNA shown in spheres with 5ʹ-3ʹ direction indicated. The approximate location of the buried C-terminal residue A859 is indicated. (D) Surface representation of AGO2 (4OLB) showing sites of tryptophan binding and the N-terminal most residue (A22) seen in the electron density. Residues 1–21 were not observed in the data. (E) pLDDT values for predictions of native AGO2 (solid black line) and C-terminal halo-tagged AGO2 and relative solvent accessible surface area (QASA, Å 2 ; red line) calculated using PDB entry 4OLB .

Article Snippet: Single-cell clones were screened for loss of AGO2 expression by immunoblotting using rabbit anti-AGO2 (Sino Biological 101,620-T36).

Techniques: Residue, Binding Assay, Sequencing, Solvent

AGO2 and other protein factors involved in miRNA-mediated regulation can associate with chromatin. Western blots showing ( A ) AGO2 localization and purity of cytoplasm (CY), nucleoplasm (NP), and chromatin (CH) in wild-type samples ( N = 3), ( B ) purity [calnexin for endoplasmic reticulum (ER)] and localization of DROSHA, Dicer, TNRC6A, and AGO1–4 ( N = 3), and ( C ) AGO2 localization in the nuclear localization sequence (NLS)-AGO2 knock-in cell line ( N = 3).

Journal: Nucleic Acids Research

Article Title: Nuclear Argonaute:miRNA complexes recognize target sequences within chromatin-associated RNA and silence gene expression

doi: 10.1093/nar/gkaf800

Figure Lengend Snippet: AGO2 and other protein factors involved in miRNA-mediated regulation can associate with chromatin. Western blots showing ( A ) AGO2 localization and purity of cytoplasm (CY), nucleoplasm (NP), and chromatin (CH) in wild-type samples ( N = 3), ( B ) purity [calnexin for endoplasmic reticulum (ER)] and localization of DROSHA, Dicer, TNRC6A, and AGO1–4 ( N = 3), and ( C ) AGO2 localization in the nuclear localization sequence (NLS)-AGO2 knock-in cell line ( N = 3).

Article Snippet: Western blot was visualized using anti-AGO2 primary antibody (50683-RP02, SinoBiological) at a 1:4000 dilution, with TrueBlot anti-rabbit secondary antibody (18-8816-31, Rockland) at 1:8000 dilution.

Techniques: Western Blot, Sequencing, Knock-In

AGO2 interacts with target RNAs in all cellular compartments. ( A ) Schematic outlining the chimeric eCLIP protocol used for the identification of AGO2-binding sites. Distribution of reproducible AGO2 ( B ) nonchimeric and ( C ) chimeric binding peaks across genomic features in cytoplasm ( N = 2), whole nucleus ( N = 2), and chromatin ( N = 2) fractions. Chimeric binding peaks only include chimeric reads that include miRNAs that map to the miRGeneDB database . ( D ) Percentage of chimeric miRNAs from the top eight miRNA families sharing the same seed sequence.

Journal: Nucleic Acids Research

Article Title: Nuclear Argonaute:miRNA complexes recognize target sequences within chromatin-associated RNA and silence gene expression

doi: 10.1093/nar/gkaf800

Figure Lengend Snippet: AGO2 interacts with target RNAs in all cellular compartments. ( A ) Schematic outlining the chimeric eCLIP protocol used for the identification of AGO2-binding sites. Distribution of reproducible AGO2 ( B ) nonchimeric and ( C ) chimeric binding peaks across genomic features in cytoplasm ( N = 2), whole nucleus ( N = 2), and chromatin ( N = 2) fractions. Chimeric binding peaks only include chimeric reads that include miRNAs that map to the miRGeneDB database . ( D ) Percentage of chimeric miRNAs from the top eight miRNA families sharing the same seed sequence.

Article Snippet: Western blot was visualized using anti-AGO2 primary antibody (50683-RP02, SinoBiological) at a 1:4000 dilution, with TrueBlot anti-rabbit secondary antibody (18-8816-31, Rockland) at 1:8000 dilution.

Techniques: Binding Assay, Sequencing

HMGA2 RNA is bound by AGO2 in all compartments of the cell. Representative IGV browser images of chimeric eCLIP reads within the 3′-UTR of HMGA2 in the ( A ) cytoplasm, ( B ) nucleus, and ( C ) chromatin. HMGA2 is located on chromosome 12 (chr12). Peak height is defined as read density in reads per million (RPM). All AGO2 peaks are reproducible and meet the following criteria: log2FC > 3 (IP versus input) at least three reads per peak.

Journal: Nucleic Acids Research

Article Title: Nuclear Argonaute:miRNA complexes recognize target sequences within chromatin-associated RNA and silence gene expression

doi: 10.1093/nar/gkaf800

Figure Lengend Snippet: HMGA2 RNA is bound by AGO2 in all compartments of the cell. Representative IGV browser images of chimeric eCLIP reads within the 3′-UTR of HMGA2 in the ( A ) cytoplasm, ( B ) nucleus, and ( C ) chromatin. HMGA2 is located on chromosome 12 (chr12). Peak height is defined as read density in reads per million (RPM). All AGO2 peaks are reproducible and meet the following criteria: log2FC > 3 (IP versus input) at least three reads per peak.

Article Snippet: Western blot was visualized using anti-AGO2 primary antibody (50683-RP02, SinoBiological) at a 1:4000 dilution, with TrueBlot anti-rabbit secondary antibody (18-8816-31, Rockland) at 1:8000 dilution.

Techniques:

SESN3 serve as a miR-23b sponge. ( A , B ) Expression changes of SESN3 following transfection with miR-23b mimics or inhibitor; ( C ) the predicted results of binding sites of SESN3 and miR-23b; ( D ) the sequence of psiCHECK2-circIGF1R-Wt and psiCHECK2-circIGF1R-Mut; ( E ) the results of dual-luciferase reporter assay; ( F ) the results of AGO2-RIP assay; ( G , H ) the results of miR-23b pulldown. Note: * indicted significant difference at 0.05 level, and ** indicted significant difference at 0.01 level.

Journal: Cells

Article Title: MiR-23b Promotes Porcine Preadipocyte Differentiation via SESN3 and ACSL4

doi: 10.3390/cells11152339

Figure Lengend Snippet: SESN3 serve as a miR-23b sponge. ( A , B ) Expression changes of SESN3 following transfection with miR-23b mimics or inhibitor; ( C ) the predicted results of binding sites of SESN3 and miR-23b; ( D ) the sequence of psiCHECK2-circIGF1R-Wt and psiCHECK2-circIGF1R-Mut; ( E ) the results of dual-luciferase reporter assay; ( F ) the results of AGO2-RIP assay; ( G , H ) the results of miR-23b pulldown. Note: * indicted significant difference at 0.05 level, and ** indicted significant difference at 0.01 level.

Article Snippet: AGO2 (Boster, Pleasanton, CA, USA), and IgG antibodies (ABclonal, Wuhan, China) were used in this assay.

Techniques: Expressing, Transfection, Binding Assay, Sequencing, Luciferase, Reporter Assay

KEY RESOURCES TABLE

Journal: Cell reports

Article Title: The structural basis for RNA slicing by human Argonaute2

doi: 10.1016/j.celrep.2024.115166

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: pcDNA3.3-3xFLAG-SUMO Eu1 -HsAGO2(R710A, H712A) , This paper , Addgene ID: 231383.

Techniques: Virus, Recombinant, Magnetic Beads, Purification, Protease Inhibitor, Staining, Plasmid Preparation, Software, Sequencing, Chromatography, Size-exclusion Chromatography